L Number	Hits	<u> </u>	DB	Time stamp
1	635	proteasome with inhibitor	USPAT;	2004/07/30 16:39
			US-PGPUB;	·
			EPO; JPO;	
			DERWENT	
2	48	(proteasome with inhibitor) same	USPAT;	2004/07/30 16:26
		(daunorubicin or doxorubicin or	US-PGPUB;	
		mitoxantraone or bisanthrene)	EPO; JPO;	1
			DERWENT	
3	131	(proteasome with inhibitor) and	USPAT;	2004/07/30 16:50
		(daunorubicin or doxorubicin or	US-PGPUB;	
		mitoxantraone or bisanthrene)	EPO; JPO;	
			DERWENT	
4	0	((proteasome with inhibitor) and	USPAT;	2004/07/30 16:26
		(daunorubicin or doxorubicin or	US-PGPUB;	
		mitoxantraone or bisanthrene)) not	EPO; JPO;	
		(proteasome with inhibitor)	DERWENT	
5	83	j -	USPAT;	2004/07/30 16:26
Ĭ	0.5	(daunorubicin or doxorubicin or	US-PGPUB;	2004/07/30 10:20
		mitoxantraone or bisanthrene)) not		
		• •	EPO; JPO;	
		((proteasome with inhibitor) same	DERWENT	
•		(daunorubicin or doxorubicin or		
_	800	mitoxantraone or bisanthrene))		
6	732	proteasome with inhibit\$8	USPAT;	2004/07/30 17:14
			US-PGPUB;	
			EPO; JPO;	
			DERWENT	
7	137	(proteasome with inhibit\$8) and	USPAT;	2004/07/30 17:14
		(daunorubicin or doxorubicin or	US-PGPUB;	
		mitoxantraone or bisanthrene)	EPO; JPO;	
		,	DERWENT	1
8	89	((proteasome with inhibit\$8) and	USPAT;	2004/07/30 16:41
1		(daunorubicin or doxorubicin or	US-PGPUB;	2004/07/30 10:41
		mitoxantraone or bisanthrene)) not	EPO; JPO;	
ŀ		((proteasome with inhibitor) same	DERWENT	
		(daunorubicin or doxorubicin or	DEKWENI	
9	6	mitoxantraone or bisanthrene))	HODAM.	2004/07/20 16 46
,	ъ	((proteasome with inhibit\$8) and	USPAT;	2004/07/30 16:42
		(daunorubicin or doxorubicin or	US-PGPUB;	
]		mitoxantraone or bisanthrene)) not	EPO; JPO;	
		((proteasome with inhibitor) and	DERWENT	
		(daunorubicin or doxorubicin or		
		mitoxantraone or bisanthrene))		
LO	589	(proteasome with inhibit\$8) and (cancer\$6	USPAT;	2004/07/30 16:45
		or tumor\$10 or neoplasm\$6 or proliferative	US-PGPUB;	
		or antiproliferative or tumour\$10)	EPO; JPO;	
			DERWENT	
11	287	(proteasome with inhibit\$8) same (cancer\$6	USPAT;	2004/07/30 16:50
ļ	İ	or tumor\$10 or neoplasm\$6 or proliferative	US-PGPUB;	
		or antiproliferative or tumour\$10)	EPO; JPO;	
			DERWENT	
12	105	((proteasome with inhibit\$8) same	USPAT;	2004/07/30 17:36
	100	(cancer\$6 or tumor\$10 or neoplasm\$6 or		2007/01/30 1/:30
		-	US-PGPUB;	
		proliferative or antiproliferative or	EPO; JPO;	
		tumour\$10)) and (daunorubicin or	DERWENT	
		doxorubicin or mitoxantraone or		
		bisanthrene or anthracyclene)		
L3	302	((proteasome with inhibit\$8) and (cancer\$6	USPAT;	2004/07/30 17:04
		or tumor\$10 or neoplasm\$6 or proliferative	US-PGPUB;	
		or antiproliferative or tumour\$10)) not	EPO; JPO;	
		((proteasome with inhibit\$8) same	DERWENT	
		(cancer\$6 or tumor\$10 or neoplasm\$6 or		
		proliferative or antiproliferative or	:	
l		DIOITICIONI DE OT SUNTO LICITATIONE DI	l .	

				
14	31	1,11	USPAT;	2004/07/30 17:10
		(cancer\$6 or tumor\$10 or neoplasm\$6 or	US-PGPUB;	
		proliferative or antiproliferative or	EPO; JPO;	
·		tumour\$10)) not ((proteasome with	DERWENT	
		inhibit\$8) same (cancer\$6 or tumor\$10 or		
		neoplasm\$6 or proliferative or		
		antiproliferative or tumour\$10))) and		
		(daunorubicin or doxorubicin or		
		mitoxantraone or bisanthrene or		
		anthracyclene)		
15	186			
	100	lactacystin	USPAT;	2004/07/30 17:10
			US-PGPUB;	·
			EPO; JPO;	
1.0			DERWENT	
16	11	((()	USPAT;	2004/07/30 17:11
		doxorubicin or mitoxantraone or	US-PGPUB;	
		bisanthrene or anthracyclene)	EPO; JPO;	
			DERWENT	
17	16346	(proteolysis or degradation) with	USPAT;	2004/07/30 17:16
		inhibit\$8	US-PGPUB;	2001/01/00 17:10
			EPO; JPO;	
			DERWENT	
18	1236	((proteolysis or degradation) with	USPAT;	2004/07/20 17:16
		inhibit\$8) and (daunorubicin or	1	2004/07/30 17:16
		doxorubicin or mitoxantraone or	US-PGPUB;	
	!	bisanthrene)	EPO; JPO;	
19	6	,	DERWENT	
	•	(\P-000-1000 01 dogradactom, with	USPAT;	2004/07/30 17:17
		inhibit\$8) same (daunorubicin or	US-PGPUB;	
		doxorubicin or mitoxantraone or	EPO; JPO;	
		bisanthrene)	DERWENT	[
20	4065	The second secon	USPAT;	2004/07/30 17:16
		degradation)) with inhibit\$8	US-PGPUB;	
			EPO; JPO;]
			DERWENT	İ
22	2	((proteolysis or (protein with	USPAT;	2004/07/30 17:17
		degradation)) with inhibit\$8) same	US-PGPUB;	2001,01,00 1,11
		(daunorubicin or doxorubicin or	EPO; JPO;	
		mitoxantraone or bisanthrene)	DERWENT	
21	704		USPAT;	2004/07/30 17:19
		degradation)) with inhibit\$8) and	US-PGPUB;	2004/07/30 17:19
		(daunorubicin or doxorubicin or	1	
		mitoxantraone or bisanthrene)	EPO; JPO;	
23	34		DERWENT	
23	34	' I ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	USPAT;	2004/07/30 17:20
		same (proteasome with inhibit\$8)	US-PGPUB;	1
			EPO; JPO;	
1 ~ 4	0065		DERWENT	
24	2067	1 - Constitution of action of	USPAT;	2004/07/30 17:37
		mitoxantraone or bisanthrene or	US-PGPUB;	
		anthracyclene)	EPO; JPO;	
			DERWENT]
25	42	p53 with (daunorubicin or doxorubicin or	USPAT;	2004/07/30 17:37
		mitoxantraone or bisanthrene or	US-PGPUB;	=====================================
		anthracyclene)	EPO; JPO;	
<u> </u>			DERWENT	

Set	Items	Description
S1	184744	
		OR ANTHRACYCLENE
S2	307	S1 AND PROTEASOME AND INHIBIT?
S3	188	RD (unique items)
S4	8	S3 AND PY<1998
S5	7411	PROTEASOME AND INHIBIT? AND (CANCER? OR TUMOR? OR NEOPLASM?
		OR PROLIFERATIVE OR ANTIPROLIFERATIVE)
S6	1313	S5 AND P53
S7	3520	S1 AND P53
S8	101	S7 AND (PROTEOLYSIS OR DEGRADATION) AND INHIBIT?
S9	67	RD (unique items)
S10	8	S9 AND PY<1998
S11	4432	LACTACYSTIN
S12	42	S11 AND S1
S13	28	RD (unique items)
S14	0	S13 AND PY<1998
S15	336	S1 AND PROTEASOME
S16	29	S15 NOT S2
S17	12	RD (unique items)